Phase 3 NPC study completion positions Rafael (NYSE: RFL) for NDA filing
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Rafael Holdings, Inc. announced that the last patient has completed the final 96‑week visit in its pivotal Phase 3 TransportNPC™ study of Trappsol® Cyclo™ for Niemann‑Pick Disease Type C. The trial enrolled 94 patients across 27 sites in 13 countries, plus a 10‑patient pediatric sub‑study.
Topline data from the main study cohort are expected in the second half of 2026. The company has already held a pre‑NDA meeting with the FDA and expects to submit a New Drug Application in the second half of 2026. The FDA has also acknowledged that the company’s U.S. Expanded Access Program can proceed.
Positive
- None.
Negative
- None.
Insights
Pivotal Phase 3 completion and pre-NDA path mark a major regulatory milestone.
Rafael Holdings reports completion of the last 96‑week visit in its pivotal Phase 3 TransportNPC™ trial of Trappsol® Cyclo™ in Niemann‑Pick Disease Type C. With 94 patients across 27 sites in 13 countries, this is described as a comprehensive, controlled pivotal study in this rare disease.
The company cites pediatric sub‑study data with 80% of patients showing improved or stable CGI scores and no serious adverse events considered related to the drug. It also notes completion of a pre‑NDA FDA meeting and plans to submit an NDA in the second half of 2026, alongside FDA acknowledgement of a U.S. Expanded Access Program.
If the forthcoming topline data in the second half of 2026 are favorable and the NDA proceeds, Trappsol® Cyclo™ could transition Rafael from a development-stage to a commercial-stage biotechnology company in NPC, a high unmet-need market, as characterized in the announcement.
8-K Event Classification
4 items: 2.02, 7.01, 8.01, 9.01
4 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Final study visit duration: 96-week study visit
Patients in main study: 94 patients
Study sites: 27 sites
+5 more
8 metrics
Final study visit duration
96-week study visit
Final visit completed in pivotal Phase 3 TransportNPC trial
Patients in main study
94 patients
Enrolled in Phase 3 TransportNPC study across global sites
Study sites
27 sites
Locations participating in TransportNPC Phase 3 trial
Countries involved
13 countries
Global footprint of TransportNPC Phase 3 study
Pediatric sub-study patients
10 patients
Single-arm pediatric sub-study ages newborn to 3 years
Pediatric CGI outcome rate
80% of patients
Improved or stable CGI scores with no serious related AEs
Topline data timing
Second half of 2026
Expected announcement of main cohort Phase 3 topline data
NDA submission target
Second half of 2026
Planned timing to submit NDA for Trappsol Cyclo
Key Terms
pivotal Phase 3, Topline data, pre-NDA meeting, Expanded Access Program (EAP), +2 more
6 terms
pivotal Phase 3 medical
"the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™"
A pivotal Phase 3 is a large, final clinical trial designed to show whether a new treatment actually works and is safe enough for regulatory approval. Think of it as the product’s final exam or full dress rehearsal: positive results are the main evidence regulators use to decide if the drug can be sold, while negative or ambiguous results can halt approval and value. Investors watch these trials closely because their outcomes strongly affect a company’s future sales prospects, regulatory risk, and stock value.
Topline data financial
"Topline data from the main study cohort is expected to be known"
Topline data are the initial, high-level results from a clinical study that show whether the main goals of the trial were met, much like the headline of a news story that summarizes the most important point. Investors care because these early outcomes quickly indicate a drug’s commercial potential and regulatory path — positive topline results can boost a company’s value, while disappointing ones can sharply reduce expected future revenue.
pre-NDA meeting regulatory
"The company has had a pre-NDA meeting with the FDA"
A pre-NDA meeting is a planned discussion between a drug developer and the medicines regulator held before submitting a New Drug Application, where the company presents its clinical, safety, and manufacturing data and asks specific questions about what the regulator expects for approval. It matters to investors because it can reveal whether a filing is on solid footing, identify potential gaps that could delay or derail approval, and reduce surprise regulatory setbacks—think of it as a dress rehearsal with the referee before the final match.
Expanded Access Program (EAP) regulatory
"acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed"
An expanded access program (EAP) lets people with serious or life‑threatening conditions use a drug or therapy that has not yet received full approval, when they cannot join clinical trials. Think of it like giving a small group early access to a product still under review; for investors it matters because EAPs can reveal real‑world safety or effectiveness signals, affect public perception and regulatory review, and provide limited early demand indicators that influence a company’s risk and value.
New Drug Application (NDA) regulatory
"expects to submit an NDA in second half of calendar 2026"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What did Rafael Holdings (RFL) announce about its Phase 3 TransportNPC study?
Rafael Holdings announced that the last patient has completed the final 96‑week visit in its pivotal Phase 3 TransportNPC study of Trappsol Cyclo for Niemann‑Pick Disease Type C, marking completion of patient follow-up in this late-stage trial.
How large and global is Rafael Holdings’ TransportNPC Phase 3 study for NPC?
The TransportNPC Phase 3 study enrolled 94 patients across 27 sites in 13 countries. This makes it a broad, controlled pivotal trial in Niemann‑Pick Disease Type C, providing a wide geographic and clinical basis for evaluating Trappsol Cyclo.
When does Rafael Holdings expect topline data from the TransportNPC Phase 3 trial?
Rafael Holdings expects topline data from the main cohort of the TransportNPC Phase 3 study to be known and announced in the second half of 2026. These results will be central to assessing Trappsol Cyclo’s performance in Niemann‑Pick Disease Type C.
What regulatory interactions with the FDA has Rafael Holdings reported for Trappsol Cyclo?
The company reports having completed a pre‑NDA meeting with the FDA and expects to submit a New Drug Application in the second half of 2026. It also received FDA acknowledgement that its U.S. Expanded Access Program for Trappsol Cyclo can proceed.
What were the key findings from Rafael Holdings’ pediatric sub-study in NPC?
In the single‑arm pediatric sub‑study for newborns to age three, 80% of patients’ CGI scores improved or remained stable, with no serious adverse events considered related to Trappsol Cyclo. These data were presented at WORLDSymposium 2026 and support its potential in NPC.
How does Rafael Holdings describe the potential impact of Trappsol Cyclo on its business?
Rafael Holdings states that NPC is a high‑unmet‑need market and that successful development of Trappsol Cyclo could help transition the company into a commercial‑stage biotechnology business, potentially creating substantial long‑term value if regulatory and clinical milestones are achieved.